Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kuoxinfang granules is a Traditional Chinese Medicine (TCM) herbal formulation developed by Longhua Hospital, Shanghai University of Traditional Chinese Medicine, for the treatment of dilated cardiomyopathy (DCM) and chronic heart failure. The formulation is specifically designed to address the TCM syndrome of Qi and Yin deficiency with blood stasis. As an adjunct to conventional Western medical therapy, Kuoxinfang granules aims to improve myocardial function, alleviate clinical symptoms of heart failure, and enhance patient quality of life. Clinical evaluation of the drug, such as in the ChiCTR2300068937 trial, focuses on its impact on left ventricular ejection fraction (LVEF), N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and TCM symptom scores in adult patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kuoxinfang granules.